Myeloma treatment still remains a challenge for a vast number of patients. Patients with standard risk disease who go into MRD negativity do tend to enjoy long remissions. But patients with high-risk disease and patients who remain MRD positive and do not go into deep remissions or relapse early, that continues to remain a challenge. Therefore, giving appropriate sequential therapy as well as entering patients into clinical trials and giving patients continuous therapy appears to be a way of managing these myeloma patients...
Myeloma treatment still remains a challenge for a vast number of patients. Patients with standard risk disease who go into MRD negativity do tend to enjoy long remissions. But patients with high-risk disease and patients who remain MRD positive and do not go into deep remissions or relapse early, that continues to remain a challenge. Therefore, giving appropriate sequential therapy as well as entering patients into clinical trials and giving patients continuous therapy appears to be a way of managing these myeloma patients. With regards to high-risk therapy, there are now trials reporting that continuous applications of treatment for these patients improves the outcomes for these patients. This happens by pushing more patients into MRD negativity as has been shown in the MUK nine b trial presented by Martin Kaiser and Matthew Jenner. This approach has also been shown by the CONCEPT, German study, and therefore in the UK, in the RADAR trial, we’ve now amended the study for high-risk patients to include continuous therapy. And we hope that would make a difference for these patients, these results we are waiting to see.